Business Wire

Recover™ Wins the Ryan Young Climate+ Award at the Textile Sustainability Conference 2021 Affirming its Mission to Achieve Circular Fashion for All

Share

Recover™, a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends, has won the Ryan Young Climate+ Award at the Textile Sustainability Conference 2021. The company was recognized for its overall commitment to meeting the Climate+ strategy goal, thanks to its work with key industry stakeholders to drive change, establish a new circular supply chain, and scale its production capacity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005635/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In its first year of existence, the Ryan Young Climate+ Awards recognize leaders within the textile supply network from around the world who have demonstrated leadership and vision in the effort to develop industry climate solutions in 2020. Organized by Textile Exchange, a global nonprofit that creates leaders in the preferred fiber and materials industry, the award acknowledges the efforts of Recover™ in its pursuit to achieve circular fashion for all through its sustainable and cost-effective plug-in-play solution.

Recover™ is an innovative textile producer that has been pioneering sustainable materials and recycling since 1947. The company recycles post-industrial and post-consumer cotton waste, replacing the need to cultivate cotton, dramatically reducing water waste, limiting the use of dyes through its RColorBlend system, and reducing textile landfill waste. By integrating its cotton into the supply chain, Recover™ also helps brands and retailers to meet their climate goals and make a significant positive environmental impact.

To support the massive and accelerating demand from brands, Recover™ is rapidly scaling the production of its recycled cotton fiber close to textile waste manufacturing hubs, whilst also dedicating one-third of its capacity to post-consumer recycling by 2025. It is the first mover and trusted thought leader to do so in the recycled cotton fiber space.

“As a longstanding member and supporter of Textile Exchange we are truly honored to receive this award,” said Helene Smits, Chief Sustainability Officer at Recover™. “For Recover™, being recognized as a Climate leader motivates us to be even more committed to be an agent of change in this industry. We must act now as an industry to achieve the climate targets and contribute to resilient ecosystems in line with the 2030 Climate+ vision that Ryan Young developed and presented at Textile Exchange conference in 2019.”

“We are honoring Ryan Young’s pioneering efforts with the creation of these awards. He often used to say, 'Do we want to be someone who is part of the solution or someone who is part of the continued problem?' I think he would agree that all of today’s winners want to be the solution-leaders,” said La Rhea Pepper, CEO and Co-Founder at Textile Exchange.

ABOUT RECOVER™

Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.

As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets. Recover™ was honored in Fast Company’s Innovation by Design Awards for 2021 in the Sustainability and Materials categories. For more information, visit www.recoverfiber.com and follow @recoverfiber on social media.

ABOUT TEXTILE EXCHANGE

Textile Exchange is a global nonprofit that creates leaders in the sustainable fiber and materials industry. The organization manages and promotes a suite of six leading industry standards, as well as collects and publishes critical industry data and insights that enable brands and retailers to measure, manage and track their use of preferred fiber and materials.

With more than 600 members who represent leading brands, retailers and suppliers, Textile Exchange has, for years, been positively impacting climate through accelerating the use of preferred fibers across the global textile industry and is now making it an imperative goal through its 2030 Strategy: Climate+. Under the Climate+ strategic direction, Textile Exchange will be the driving force for urgent climate action with a goal of 45% reduced CO2 emissions from textile fiber and material production by 2030.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hannah Wesselby
Hannah.wesselby@recoverfiber.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye